AIM: To investigate and compare topoisomerase II-alpha expression in benign prostatic hyperplasia (BPH), prostate cancer of varying Gleason scores and hormone-insensitive prostate cancer. METHODS: The immunohistochemical expression of topoisomerase II-alpha antibody in the above-mentioned diagnostic categories was investigated and compared. RESULTS: Increased expression of topoisomerase II-alpha was seen in the prostate cancers of Gleason scores 7 and 8-10 (p = 0.000) compared with prostate cancers of Gleason score 6 and BPH (p = 0.245). Statistically significant differences were found in the topoisomerase II-alpha gene expression between prostate cancers categorised by Gleason Score. Also, increased expression of topoisomerase II-alpha was seen in the known hormone-resistant prostate carcinomas compared with prostate cancers with no hormone treatment in the subgroup with Gleason scores 8-10, which approached statistical significance (p = 0.081). No statistically significant difference was observed in topoisomerase II-alpha expression between the groups with BPH and prostate carcinoma of Gleason score 6 (p = 0.245). CONCLUSION: Topoisomerase II-alpha expression was found to increase with the known prognostic marker Gleason score and with hormone insensitivity. Objective evidence is provided for clinical trials with drugs targeting topoisomerase II-alpha to be targeted to patients with prostate cancers of Gleason Score >6 and, in particular, prostate cancers of Gleason Scores 8-10.
AIM: To investigate and compare topoisomerase II-alpha expression in benign prostatic hyperplasia (BPH), prostate cancer of varying Gleason scores and hormone-insensitive prostate cancer. METHODS: The immunohistochemical expression of topoisomerase II-alpha antibody in the above-mentioned diagnostic categories was investigated and compared. RESULTS: Increased expression of topoisomerase II-alpha was seen in the prostate cancers of Gleason scores 7 and 8-10 (p = 0.000) compared with prostate cancers of Gleason score 6 and BPH (p = 0.245). Statistically significant differences were found in the topoisomerase II-alpha gene expression between prostate cancers categorised by Gleason Score. Also, increased expression of topoisomerase II-alpha was seen in the known hormone-resistant prostate carcinomas compared with prostate cancers with no hormone treatment in the subgroup with Gleason scores 8-10, which approached statistical significance (p = 0.081). No statistically significant difference was observed in topoisomerase II-alpha expression between the groups with BPH and prostate carcinoma of Gleason score 6 (p = 0.245). CONCLUSION: Topoisomerase II-alpha expression was found to increase with the known prognostic marker Gleason score and with hormone insensitivity. Objective evidence is provided for clinical trials with drugs targeting topoisomerase II-alpha to be targeted to patients with prostate cancers of Gleason Score >6 and, in particular, prostate cancers of Gleason Scores 8-10.
Authors: M A Dimopoulos; C Panopoulos; C Bamia; C Deliveliotis; G Alivizatos; D Pantazopoulos; C Constantinidis; A Kostakopoulos; I Kastriotis; A Zervas; G Aravantinos; C Dimopoulos Journal: Urology Date: 1997-11 Impact factor: 2.649
Authors: A Hoos; M J Urist; A Stojadinovic; S Mastorides; M E Dudas; D H Leung; D Kuo; M F Brennan; J J Lewis; C Cordon-Cardo Journal: Am J Pathol Date: 2001-04 Impact factor: 4.307
Authors: J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi Journal: Nat Med Date: 1998-07 Impact factor: 53.440
Authors: Olakunle O Kassim; Robert L Copeland; Hilaire M Kenguele; Sergei Nekhai; Kwashie A Ako-Nai; Yasmine M Kanaan Journal: Anticancer Res Date: 2015-03 Impact factor: 2.480
Authors: John C Cheville; R Jeffrey Karnes; Terry M Therneau; Farhad Kosari; Jan-Marie Munz; Lori Tillmans; Eati Basal; Laureano J Rangel; Eric Bergstralh; Irina V Kovtun; C D Savci-Heijink; Eric W Klee; George Vasmatzis Journal: J Clin Oncol Date: 2008-08-20 Impact factor: 44.544
Authors: Marina França de Resende; Samantha Vieira; Ludmilla Thomé Domingos Chinen; Francesco Chiappelli; Francisco Paulo da Fonseca; Gustavo Cardoso Guimarães; Fernando Augusto Soares; Ivan Neves; Simone Pagotty; Peter A Pellionisz; Andre Barkhordarian; Xenia Brant; Rafael Malagoli Rocha Journal: J Transl Med Date: 2013-02-11 Impact factor: 5.531
Authors: J L Schaefer-Klein; Stephen J Murphy; Sarah H Johnson; George Vasmatzis; Irina V Kovtun Journal: PLoS One Date: 2015-11-11 Impact factor: 3.240